/result/?code=index01
/result/journal/
/result/permit/
/hbs/
 
 
 Home > 연구성과 > 한국을 빛낸 세포치료 연구     
김효수 (Hyo-Soo Kim)
서울대학교 병원
                 [2007년 8월] 조회수 : 8322

The Lancet

Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study

Bon-Kwon Koo, Yong-Seok Kim, Kyung-Woo Park, Han-Mo Yang, Dong-A Kwon, Jin-Wook Chung, Joo-Yong Hahn, Hae-Young Lee, Jin-Shik Park, Hyun-Jae Kang, Young-Seok Cho, Tae-Jin Youn, Woo-Young Chung, In-Ho Chae, Dong-Ju Choi, Byung-Hee Oh, Young-Bae Park, Hyo-Soo Kim

Division of Cardiology, Department of Internal Medicine, Seoul National University College of Medicine, Cardiovascular Center and Cardiovascular Research Institute, Seoul National University Hospital, Seoul, South Korea

Division of Cardiology, Department of Internal Medicine, Seoul National University College of Medicine, Cardiovascular Center and Cardiovascular Research Institute, Seoul National University Hospital, Seoul, South Korea

The Lancet 2007; 370:567-574
DOI:10.1016/S0140-6736(07)61295-1

Articles

Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study

Bon-Kwon Koo MD a,   Yong-Seok Kim MD a,   Kyung-Woo Park MD a,   Han-Mo Yang MD a,   Dong-A Kwon MD a,   Jin-Wook Chung MD a,   Joo-Yong Hahn MD a,   Hae-Young Lee MD a,   Jin-Shik Park MD a,   Hyun-Jae Kang MD a,   Young-Seok Cho MD b,   Tae-Jin Youn MD b,   Woo-Young Chung MD b,   In-Ho Chae MD b,   Dong-Ju Choi MD b,   Byung-Hee Oh MD a,   Young-Bae Park MD a   and   Dr Hyo-Soo Kim MD  a 

Summary

Background

In-vitro and animal experiments have shown that the cyclo-oxygenase 2 inhibitor celecoxib can reduce formation of neointima within stents. We aimed to test whether celecoxib has similar effects in a clinical setting.

Methods

In a randomised two-centre trial, we enrolled 274 patients who had angina pectoris or a positive stress test and who had native coronary artery lesions for which implantation of paclitaxel-eluting stents was feasible. All patients were given aspirin (100 mg daily) and clopidogrel (75 mg daily). 136 patients were randomly assigned to receive celecoxib (400 mg before the intervention, and 200 mg twice daily for 6 months after the procedure). The primary endpoint was late luminal loss on quantitative coronary angiography at 6 months after the intervention. Secondary endpoints were cardiac death, non-fatal myocardial infarction, and revascularisation of the target lesion. Analysis was done on a modified intention-to-treat basis. This study is registered with ClinicalTrials.gov, number NCT00292721.

Findings

At 6 months, mean in-stent late luminal loss was lower in the celecoxib group (0·49 mm, SD 0·47) than in the control group (0·75 mm, 0·60) (absolute difference 0·26 mm; 95% CI 0·12–0·40). Frequency of secondary outcomes at 6 months was also lower in the celecoxib group, mainly because of a reduced need for revascularisation of the target lesion.

Interpretation

These data suggest that the adjunctive use of celecoxib for 6 months after stent implantation in patients with coronary artery disease is safe and can reduce the need for revascularisation of the target lesion.

Affiliationsa. Division of Cardiology, Department of Internal Medicine, Seoul National University College of Medicine, Cardiovascular Center and Cardiovascular Research Institute, Seoul National University Hospital, Seoul, South Koreab. Cardiovascular Center, Seoul National University Bundang Hospital, Gyeonggi-do, South Korea

Correspondence to: Dr Hyo-Soo Kim, Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Yongon-dong 28, Chongno-gu, Seoul, 110-744, South Korea

Keyword : celecoxib
게시물목록을 봅니다. 내용을 출력합니다.
Copyright © Innovative Research Institute for Cell Therapy.
Tel. 02-740-8969   Fax. 02-2072-0398   E-mail : irictpr@snu.ac.kr
110-744 서울특별시 종로구 대학로 101(연건동28번지) 서울대학교병원 어린이병원 별관 4층 첨단세포유전자치료센터